Water Extract of Ecklonia cava Protects against Fine Dust (PM2.5)-Induced Health Damage by Regulating Gut Health
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
To confirm the therapeutic effect of the water extract from Ecklonia cava (WEE) against PM2.5 induced systemic health damage, we evaluated gut health with a focus on the microbiota and metabolites. Systemic damage in mice was induced through PM2.5 exposure for 12 weeks in a whole-body chamber. After exposure for 12 weeks, body weight and food intake decreased, and WEE at 200 mg/kg body weight (mpk) alleviated these metabolic efficiency changes. In addition, PM2.5 induced changes in the length of the colon and fecal water content. The administration of the WEE at 200 mpk oral dose effectively reduced changes in the colon caused by PM2.5 exposure. We also attempted to confirm whether the effect of the WEE is mediated via regulation of the microbiota-gut-brain axis in mice with PM2.5 induced systemic damage. We examined changes in the fecal microbiota and gut metabolites such as short-chain fatty acids (SCFAs) and kynurenine metabolites. In the PM2.5 exposed group, a decrease in the abundance of Lactobacillus (Family: Lactobacillaceae) and an increase in the abundance of Alistipes (Family: Rikenellaceae) were observed, and the administration of the WEE showed a beneficial effect on the gut microbiota. In addition, the WEE effectively increased the levels of SCFAs (acetate, propionate, and butyrate). Furthermore, kynurenic acid (KYNA), which is a critical neuroprotective metabolite in the gut-brain axis, was increased by the administration of the WEE. Our findings suggest that the WEE could be used as a potential therapeutic against PM2.5 induced health damage by regulating gut function.
Abstract
To confirm the therapeutic effect of the water extract from Ecklonia cava (WEE) against PM2.5 induced systemic health damage, we evaluated gut health with a focus on the microbiota and metabolites. Systemic damage in mice was induced through PM2.5 exposure for 12 weeks in a whole-body chamber. After exposure for 12 weeks, body weight and food intake decreased, and WEE at 200 mg/kg body weight (mpk) alleviated these metabolic efficiency changes. In addition, PM2.5 induced changes in the length of the colon and fecal water content. The administration of the WEE at 200 mpk oral dose effectively reduced changes in the colon caused by PM2.5 exposure. We also attempted to confirm whether the effect of the WEE is mediated via regulation of the microbiota-gut-brain axis in mice with PM2.5 induced systemic damage. We examined changes in the fecal microbiota and gut metabolites such as short-chain fatty acids (SCFAs) and kynurenine metabolites. In the PM2.5 exposed group, a decrease in the abundance of Lactobacillus (Family: Lactobacillaceae) and an increase in the abundance of Alistipes (Family: Rikenellaceae) were observed, and the administration of the WEE showed a beneficial effect on the gut microbiota. In addition, the WEE effectively increased the levels of SCFAs (acetate, propionate, and butyrate). Furthermore, kynurenic acid (KYNA), which is a critical neuroprotective metabolite in the gut-brain axis, was increased by the administration of the WEE. Our findings suggest that the WEE could be used as a potential therapeutic against PM2.5 induced health damage by regulating gut function.
참고문헌 (56)
- Jia Zhang, "Parental PM2.5 Exposure-Promoted Development of Metabolic Syndrome in Offspring Is Associated With the Changes of Immune Microenvironment", Toxicological Sciences, 170(2), pp.415~426 (2019), Oxford University Press (OUP)[DOI]
- 조명행, "Comparative study of PM2.5-and PM10-induced oxidative stress in rat lung epithelial cells", Journal of Veterinary Science, 5(1), pp.11~18 (2004), 대한수의학회
- Yikai Shou, "A review of the possible associations between ambient PM2.5 exposures and the development of Alzheimer's disease", Ecotoxicology and Environmental Safety, 174, pp.344~352 (2019), Elsevier BV[DOI]
- Pengfei Fu, "The association between PM2.5 exposure and neurological disorders: A systematic review and meta-analysis", Science of The Total Environment, 655, pp.1240~1248 (2019), Elsevier BV[DOI]
- Salim SY, "Air pollution effects on the gut microbiota : a link between exposure and inflammatory disease", Gut Microbes, 5, pp.215~219 (2014)
- Wang W, "Exposure to concentrated ambient PM2.5 alters the composition of gut microbiota in a murine model", Part. Fibre Toxicol, 5, pp.17~ (2018)
- Mutlu EA, "Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome", Environ. Pollut, 240, pp.817~830 (2018)
- Więdłocha M, "Gut microbiota, kynurenine pathway and mental disorders–Review", Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 106, pp.110145~ (2021)
- Kennedy PJ, "Kynurenine pathway metabolism and the microbiota-gut-brain axis", Neuropharmacology, 112, pp.399~412 (2017)
- Dinan TG, "The microbiome-gut-brain axis in health and disease", Gastroenterol. Clin. North Am, 46, pp.77~89 (2017)
- van der Meulen TA, "The microbiome–systemic diseases connection", Oral Dis, 22, pp.719~734 (2016)
- Yiquan Chen, "Kynurenine Pathway Metabolites in Humans: Disease and Healthy States", International Journal of Tryptophan Research, 2, pp.IJTR.S2097~ (2009), SAGE Publications[DOI]
- Liang Y, "Kynurenine pathway metabolites as biomarkers in Alzheimer’s disease", Dis. Markers, 2022, pp.9484217~ (2022)
- Dong Mun Choi, "Morphological and genetic variability among Ecklonia cava (Laminariales, Phaeophyceae) populations in Korea", ALGAE, 30(2), pp.89~101 (2015), 한국조류학회I[DOI]
- Wijesekara I, "Phlorotannins from Ecklonia cava(Phaeophyceae) : Biological activities and potential health benefits", Biofactors, 36, pp.408~414 (2010)
- Wijesinghe W, "Exploiting biological activities of brown seaweed Ecklonia cava for potential industrial applications : a review", Int. J. Food Sci. Nutr, 63, pp.225~235 (2012)
- Seon Kyeong Park, "Ecklonia cava Attenuates PM2.5-Induced Cognitive Decline through Mitochondrial Activation and Anti-Inflammatory Effect", Marine Drugs, 19(3), pp.131~ (2021), MDPI AG[DOI]
- Lee S, "Anti-neuroinflammatory property of phlorotannins from Ecklonia cava on Aβ25-35-induced damage in PC12 cells", Mar. Drugs, 17, pp.7~ (2018)
- 한문, "Biological effects of blood–brain barrier disruption using a focused ultrasound", Biomedical Engineering Letters (BMEL), 7(2), pp.115~120 (2017), 대한의용생체공학회[DOI]
- Liu X, "Modulation of gut microbiota–brain axis by probiotics, prebiotics, and diet", J. Agric. Food Chem, 63, pp.7885~7895 (2015)
- 강정은, "Actinidia arguta Sprout as a Natural Antioxidant: Ameliorating Effect on Lipopolysaccharide-Induced Cognitive Impairment", Journal of Microbiology and Biotechnology, 31(1), pp.51~62 (2021), 한국미생물·생명공학회[DOI]
- Virág D, "Development, validation and application of LC–MS", MS method for quantification of amino acids, kynurenine and serotonin in human plasma, 2020, pp.180, 113018~
- Wang L-S, "LC-MS", MS-based quantification of tryptophan metabolites and neurotransmitters in the serum and brain of mice, 2019, pp.1112, 24~32
- Peters R, "Air pollution and dementia : a systematic review", J. Alzheimer's Dis, 70, pp.145~163 (2019)
- Konturek S, "Brain-gut axis and its role in the control of food intake", J. Physiol. Pharmacol, 55, pp.137~154 (2004)
- Sun L-J, "Gut hormones in microbiota-gut-brain cross-talk", Chin. Med. J, 133, pp.826~833 (2020)
- Yang M, "Effects and mechanism of constitutive TL1A expression on intestinal mucosal barrier in DSS-induced colitis", Dig. Dis. Sci, 64, pp.1844~1856 (2019)
- Wu L-H, "Protective effect of anthocyanins extract from blueberry on TNBS-induced IBD model of mice", Evid. Based Complement. Alternat. Med, 2011, pp.525462~ (2011)
- Akbari P, "Galacto-oligosaccharides protect the intestinal barrier by maintaining the tight junction network and modulating the inflammatory responses after a challenge with the mycotoxin deoxynivalenol in human Caco-2 cell monolayers and B6C3F1 mice", J. Nutr, 145, pp.1604~1613 (2015)
- Xue M, "The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer", Food Funct, 9, pp.1214~1223 (2018)
- Sun T, "Protective effect and mechanism of fucoidan on intestinal mucosal barrier function in NOD mice", Food Agric. Immunol, 31, pp.939~953 (2020)
- Carding S, "Dysbiosis of the gut microbiota in disease", Microb. Ecol. Health Dis, 26, pp.26191~ (2015)
- Ying Liu, "Intratracheally instillated diesel PM2.5 significantly altered the structure and composition of indigenous murine gut microbiota", Ecotoxicology and Environmental Safety, 210, pp.111903~ (2021), Elsevier BV[DOI]
- Isolauri E, "Probiotics : effects on immunity", Am. Clin. Nutr, 73, pp.444~450 (2001)
- Yanzhuo Kong, "The Potential of Lactobacillus spp. for Modulating Oxidative Stress in the Gastrointestinal Tract", Antioxidants, 9(7), pp.610~ (2020), MDPI AG[DOI]
- Kelley N, "The NLRP3 inflammasome : an overview of mechanisms of activation and regulation", Int. J. Mol. Sci, 20, pp.3328~ (2019)
- Bercik P, "The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice", Gastroenterology, 141, pp.599~609 (2011)[DOI]
- Xu M, "Yeast β-glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in Aβ1–42-induced AD-like mice", Int. J. Biol. Macromol, 161, pp.258~270 (2020)
- Zheng L-X, "Current trends in marine algae polysaccharides : the digestive tract, microbial catabolism, and prebiotic potential", Int. J. Biol. Macromol, 151, pp.344~354 (2020)
- Martin-Gallausiaux C, "Butyrate produced by commensal bacteria down-regulates indolamine 2, 3-dioxygenase 1(IDO-1)expression via a dual mechanism in human intestinal epithelial cells", Front. Immunol, 9, pp.2838~ (2018)
- Allison DJ, "The common inflammatory etiology of depression and cognitive impairment : a therapeutic target", J. Neuroinflamm, 11, pp.1~12 (2014)
- Charoensiddhi S, "Impact of extraction processes on prebiotic potential of the brown seaweed Ecklonia radiata by in vitro human gut bacteria fermentation", J. Funct. Foods, 24, pp.221~230 (2016)
- Mudry JM, "Direct effects of exercise on kynurenine metabolism in people with normal glucose tolerance or type 2 diabetes", Diabetes Metab. Res. Rev, 32, pp.754~761 (2016)
- Guidetti P, "Characterization of rat brain kynurenine aminotransferases I and II", J. Neurosci. Res, 50, pp.457~465 (1997)
- Cervenka I, "Kynurenines : Tryptophan’s metabolites in exercise, inflammation, and mental health", Science, 357, pp.9794~ (2017)
- Mándi Y, "The kynurenine system and immunoregulation", J. Neural Transm, 119, pp.197~209 (2012)
- Müller N, "The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment", Dialogues Clin. Neurosci, 11, pp.319~332 (2009)
- Gilles J. Guillemin, "QUINOLINIC ACID IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE", Advances in Experimental Medicine and Biology, pp.167~176 (2003), Springer US[DOI]
- Singh S, "Neuroprotective activity of curcumin in combination with piperine against quinolinic acid induced neurodegeneration in rats", Pharmacology, 97, pp.151~160 (2016)
- Stone TW, "Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection", Trends Pharmacol. Sci, 21, pp.149~154 (2000)
- Foster AC, "Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid", Neurosci. Lett, 48, pp.273~278 (1984)
- Morales-Martínez A, "Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats", Nutr. Neurosci, 20, pp.388~395 (2017)
- Parasram K, "Phytochemical treatments target kynurenine pathway induced oxidative stress", Redox Rep, 23, pp.25~28 (2018)
- Savitz J, "The kynurenine pathway : a finger in every pie", Mol. Psychiatry, 25, pp.131~147 (2020)
- Connor TJ, "Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge : a role for IFN-γ?", Neurosci. Lett, 441, pp.29~34 (2008)
- Molteni R, "Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine", Eur. Neuropsychopharmacol, 23, pp.1645~1655 (2013)